[{"from": "human", "value": "Provide a brief overview of this molecule. [B][Branch2][Ring1][#C][C@H1][Branch1][#C][C][C][C@H1][Branch1][Ring2][O][Ring1][=Branch1][C][C][=Branch1][C][=O][O][N][C][=Branch1][C][=O][C][C][=C][C][=C][S][Ring1][Branch1][O]"}, {"from": "gpt", "value": "The molecule is a \u03b2-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of vaborbactam and [Meropenem] for intravenous administration. Vaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture, when the infections are proven or strongly suspected to be caused by susceptible bacteria."}]